Latest From Sartorius AG
Irish biotech focused on Endobody vaccine candidates partners with Boston U. in CTE and U. of Texas in Alzheimer’s. Lupus Research Alliance affiliate will help Bristol conduct a Phase II trial of Tyk2 inhibitor in lupus.
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Drug Discovery Tools
- Synthesis Technologies, Production Processes
- Drug Discovery Tools
- Consumables, Central Supplies
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Sartorius Group
- Feinmechanische Werkstatt F. Sartorius
- Western Europe
- Parent & Subsidiaries
- Sartorius AG
- Senior Management
- Joachim Kreuzburg, CEO
- Contact Info
Phone: (49) 551 3080
Weender Landstrasse 94-108
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.